(HLN) Haleon - Ratings and Ratios

Haleon plc (NYSE:HLN) is a global leader in consumer healthcare, operating across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company specializes in the research, development, and distribution of a wide range of healthcare products. Its portfolio includes oral health products such as toothpastes, mouthwashes, and denture care solutions under brands like Sensodyne, Polident, and Aquafresh. Additionally, it offers vitamins and supplements under Centrum and Emergen-C, addressing consumer needs for immune support and overall wellness. Haleon also provides over-the-counter remedies for respiratory issues, pain relief, and digestive health through brands like Otrivine, Voltaren, and TUMS. The company, originally founded in 1715, rebranded as Haleon plc in February 2022, signaling its commitment to innovation and consumer-centric healthcare solutions.

From a technical perspective, Haleons stock has shown stability with an average 20-day volume of 12,013,215 shares. The stock is currently trading at $10.22, slightly above its 20-day SMA of $10.02 but aligning closely with its 50-day SMA of $10.08. The 200-day SMA of $9.78 indicates a gradual upward trend over the past year. The Average True Range (ATR) of 0.24 reflects moderate volatility, suggesting manageable risk for investors.

On the fundamental side, Haleon boasts a market capitalization of $45.625 billion, underscoring its position as a major player in the healthcare sector. The trailing P/E ratio of 24.66 and forward P/E of 20.33 suggest that investors expect moderate earnings growth in the coming year. The price-to-book ratio of 2.16 indicates that the stock is fairly valued relative to its book value, while the price-to-sales ratio of 4.06 reflects a premium for its revenue generation capabilities. The return on equity of 8.92% highlights efficient profitability, though it leaves room for improvement.